PDF herunterladen
Hamostaseologie 1986; 06(03): 131-138
DOI: 10.1055/s-0038-1655150
Originalarbeiten
Schattauer GmbH

Heparin-Kofaktor II

F. Duckert
1   Gerinnungs- und Fibrinolyselaboratorien, Kantonsspital, Basel/Schweiz
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. Juni 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

 

  • Literatur

  • 1 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos Diathes Haemorrh 1965; 13: 516-30.
    PubMedGoogle Scholar
  • 2 Bertina R M, Broekmans A W, van der Linden I K, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 1-5.
    PubMedGoogle Scholar
  • 3 Broekmans A W, Bertina R M, Reinalda-Poot J, Engesser L, Muller H P, Leeuw J A, Michels J J, Brommer E J P, Briet F. Hereditary Protein S deficiency and venous thromboembolism. A study in three Dutch families. Thromb Haemostas 1985; 53: 273-7.
    PubMedGoogle Scholar
  • 4 Briginshaw G F, Shanberge J N. Identification of two distinct heparin cofactors in human plasma. Separation and partial purification. Arch Biochem Biophys 1974; 161: 683-90.
    CrossrefPubMedGoogle Scholar
  • 5 Brighinshaw G F, Shanberge J N. Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factor X. Thromb Res 1974; 04: 463-77.
    CrossrefPubMedGoogle Scholar
  • 6 Abildgaard U. Purification of two progressive antithrombins of human plasma. Scand J Clin Lab Invest 1967; 19: 190-5.
    CrossrefPubMedGoogle Scholar
  • 7 Tollefsen D M, Majerus D W, Blank M K. A new heparin-dependent inhibitor of thrombin in human plasma. Clin Res 1981; 29: 523 (Abstract).
    PubMedGoogle Scholar
  • 8 Tollefsen D M, Blank M K. Detection of a new heparin dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-96.
    CrossrefPubMedGoogle Scholar
  • 9 Wunderwald P, Schrenk W J, Port H. Antithrombin BM from human plasma: An antithrombin binding moderately to heparin. Thromb Res 1982; 25: 177-91.
    CrossrefPubMedGoogle Scholar
  • 10 Griffith M J, Pantelakos G C, McNeely T B, Dombrose F A. Isolation and partial characterization of a second heparin cofactor of human plasma. Fed Proc 1982; 41: 502 (Abstract).
    PubMedGoogle Scholar
  • 11 Tollefsen D M, Majerus D W, Blank M K. Heparin Cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human. J Biol Chem 1982; 257: 2162-9.
    PubMedGoogle Scholar
  • 12 Yamagishi R, Niwa M, Kondo S, Sakuragawa N, Koide T. Purification and biological property of heparin cofactor II: Activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans. Thromb Res 1984; 36: 633-42.
    CrossrefPubMedGoogle Scholar
  • 13 Tran T H, Lämmle B, Zbinden B, Duckert F. Thrombin inhibition by antithrombin III (AT) and heparin cofactor II (HC II) in the presence of heparin. Improved purification of HC II. Blut 1984; 49: 131 (Zusammenfassung).
    PubMedGoogle Scholar
  • 14 Griffith M J, Noyes C M, Church F C. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J. Biol Chem 1985; 260: 2218-25.
    PubMedGoogle Scholar
  • 15 Tran T H, Lämmle B, Zbinden B, Duckert F. Heparin cofactor II: Purification and antibody production. Thromb Haemostas 1986; 55: 19-23.
    PubMedGoogle Scholar
  • 16 Jordan R, Beeler D, Rosenberg R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-13.
    PubMedGoogle Scholar
  • 17 Teien A N, Abildgaard U, Höök M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 08: 859-67.
    CrossrefPubMedGoogle Scholar
  • 18 Tollefsen D M, Pestka C A, Monafo W J. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6.
    PubMedGoogle Scholar
  • 19 Abildgaard U, Larsen M L. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res 1984; 35: 257-66.
    CrossrefPubMedGoogle Scholar
  • 20 Griffith M J, Marbet G A. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II. Biochem Biophys Res Comm 1983; 112: 663-70.
    CrossrefPubMedGoogle Scholar
  • 21 Tollefsen D M. Activation of heparin cofactor II by heparin and dermatan sulfate. Nouv Rev Fr Hematol 1984; 26: 233-7.
    PubMedGoogle Scholar
  • 22 Tollefsen D M, Peacock M E, Monafo W J. Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. Fed Proc 1984; 43: 1843.
    PubMedGoogle Scholar
  • 23 Ofosu F A, Modi G J, Smith L S, Cerskus A L, Hirsh J, Blajchman M A. Heparin sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 727-47.
    PubMedGoogle Scholar
  • 24 Griffith M J. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin. J Biol Chem 1982; 275: 7360-5.
    PubMedGoogle Scholar
  • 25 Griffith M J. The heparin-enhanced antithrombin III/thrombin reaction is saturable with respect to both thrombin and antithrombin III. J Biol Chem 1982; 257: 13899-902.
    PubMedGoogle Scholar
  • 26 Griffith M J, Marbet G A. Kinetics of the heparin cofactor II/thrombin reaction catalyzed by heparin and dermatan sulfate. Fed Proc 1983; 42: 1861.
    PubMedGoogle Scholar
  • 27 Marbet G A, Griffith M J. Catalysis of the heparin cofactor II/thrombin reaction by dermatan sulfate selective and saturable with respect to both proteins. Persönliche Mitteilung..
    PubMedGoogle Scholar
  • 28 Griffith M H. Heparin-catalyzed inhibitor/ protease reactions: Kinetic evidence for a common mechanism of action of heparin. Proc Natl Acad Sci USA 1983; 80: 5460-4.
    CrossrefPubMedGoogle Scholar
  • 29 Hurst R E, Poon M C. Independence of heparin charge density and antithrombinbinding domains in thrombin inhibition by antithrombin and heparin cofactor II. J Clin Invest 1983; 72: 1042-5.
    CrossrefPubMedGoogle Scholar
  • 30 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-505.
    PubMedGoogle Scholar
  • 31 Pecon J M, Blackburn M N. Pyridoxylation of essential lysines in the heparin-binding site of antithrombin III. J Biol Chem 1984; 259: 935-8.
    PubMedGoogle Scholar
  • 32 Church F C, Griffith M J. Evidence for essential lysines in heparin cofactor II. Biochem Biophys Res Comm 1984; 124: 745-51.
    CrossrefPubMedGoogle Scholar
  • 33 Church F C, Griffith M J. Chemical modification of heparin cofactor II by sulfhydryldirected reagents. Fed Proc 1984; 44: 1433.
    PubMedGoogle Scholar
  • 34 Witt I, Kaiser C, Schrenk W J, Wunderwald P. Aminoacid composition and N-terminal sequence of antithrombin BM. Thromb Res 1983; 32: 513-8.
    CrossrefPubMedGoogle Scholar
  • 35 Griffith M J, Noyes C M, Church F C. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-25.
    PubMedGoogle Scholar
  • 36 Chang J Y, Tran T H. Antithrombin III Basel. J Biol Chem 1986; 261: 1174-6.
    PubMedGoogle Scholar
  • 37 Griffith M J, Noyes C M, Tyndall J A, Church F C. Structural evidence for leucine at the reactive site of heparin cofactor II. Biochemistry 1985; 24: 6777-82.
    CrossrefPubMedGoogle Scholar
  • 38 Petersen T E, Dudek-Wojciechowska G, Sottrup-Jensen L, Magnusson S. In: The Physiological Inhibitors of Blood Coagulation and Fibrinolysis. Collen D, Wiman B, Verstraete M. (eds). North-Holland, Amsterdam: Elsevier; 1979: 43-54.
  • 39 Church F C, Noyes C M, Griffith M J. Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sei USA 1985; 82: 8431-4.
    PubMedGoogle Scholar
  • 40 Griffith M J, Noyes C M, Allen N, Villanueva G B. Evidence for structurally similar regions in antithrombin III and heparin cofactor II. Fed Proc 1984; 43: 1963.
    PubMedGoogle Scholar
  • 41 Parker K A, Tollefsen D M. The protease specificity of heparin cofactor II. J Biol Chem 1985; 260: 3501-5.
    PubMedGoogle Scholar
  • 42 Tran T H, Duckert F. Heparin cofactor determination. Levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation. Thromb Haemostas 1984; 52: 112-6.
    PubMedGoogle Scholar
  • 43 Tran T H, Zbinden B, Lämmle B, Duckert F. Methodology and clinical significance of heparin cofactor II. Semin Thromb Haemostas 1985; 11: 342-6.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 44 Sié P, Dupouy D, Pichon J, Boneu B. Turnover study of heparin cofactor II in healthy man. Thromb Haemostas 1985; 54: 635-8.
    PubMedGoogle Scholar
  • 45 Jaffe E A, Armellino D, Tollefsen D M. Biosynthesis of functionally active heparin cofactor II by a human hepatoma-derived cell line. Biochem Biophys Res Comm 1985; 132: 368-74.
    CrossrefPubMedGoogle Scholar
  • 46 Tran T H, Duckert F. Influence of heparin cofactor II (HC II) on the determination of antithrombin III (AT III). Thromb Res 1985; 40: 571-6.
    CrossrefPubMedGoogle Scholar
  • 47 Friberger P, Egberg N, Holmer E, Hellgren M, Blombäck M. Antithrombin assay, the use of human or bovine thrombin and the observation of a “second” heparin cofactor. Thromb Res 1982; 25: 433-6.
    CrossrefPubMedGoogle Scholar
  • 48 Tran T H, Marbet G A, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; II: 413-4.
    PubMedGoogle Scholar
  • 49 Sié P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; II: 414-6.
    PubMedGoogle Scholar
  • 50 Griffith M J, Tyndall J A, Noyes C M, Church F C. Enzymatic inactivation of heparin cofactor II by a proteinase (proteinase-1) isolated from Echis carinatus venom. Thromb Res 1985; 39: 659-69.
    CrossrefPubMedGoogle Scholar
  • 51 Griffith M J, Carraway T, White G C, Dombrose F A. Heparin cofactor activities in a family with hereditary antithrombin III deficiency: Evidence for a second heparin cofactor in human plasma. Blood 1983; 61: 111-8.
    PubMedGoogle Scholar
  • 52 Lijnen H R, Hoylaerts M, Collen D. Heparin binding properties of human histidinerich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803-8.
    PubMedGoogle Scholar
  • 53 Niwa M, Yamagishi R, Kondo S I, Sakuragawa N, Koide T. Histidine-rich glycoprotein inhibits the antithrombin activity of heparin cofactor II in the presence of heparin or dermatan sulfate. Thromb Res 1985; 37: 237-40.
    CrossrefPubMedGoogle Scholar
  • 54 Tollefsen D M, Pestka C A. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. J Clin Invest 1985; 75: 496-501.
    CrossrefPubMedGoogle Scholar
  • 55 Sié P, Fernandez F, Caranobe C, Gabaig A M, Boneu B. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate. Thromb Res 1984; 35: 231-6.
    CrossrefPubMedGoogle Scholar
  • 56 Scully M F, Kakkar V V. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54). Thromb Res 1984; 36: 187-94.
    CrossrefPubMedGoogle Scholar
  • 57 Lindahl U, Höök M. Glycosaminoglycans and their binding to biological macromolecules. Ann Rev Biochem 1978; 47: 385-417.
    CrossrefPubMedGoogle Scholar
  • 58 Bianchini P, Osima B, Parma B, Nader H B, Dietrich C P. Lack of correlation between »in vitro« and »in vivo« antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent »in vivo«. Thromb Res 1985; 40: 597-607.
    CrossrefPubMedGoogle Scholar
  • 59 Kindness G, Long W F, Williamson F B. The anticoagulant activity of dermatan sulphates: Evidence against the involvement of antithrombin III. Br J Pharmacol 1981; 72: 81-8.
    CrossrefPubMedGoogle Scholar
  • 60 Ofosu F A, Fernandez F, Gauthier D, Buchanan M R. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Haemost 1985; 11: 113-37.
    PubMedGoogle Scholar
  • 61 Swedenborg J, Dryjski M, Olsson P. Inactivation of thrombin by the aortic endothelium. Thromb Haemostas 1983; 50: 635-8.
    PubMedGoogle Scholar
  • 62 Fischer A M, Dautzenberg M D, Aurousseau M H, Béguin S, Goudemand J, Hemker H C. Comparison between the effect of pentosan polysulphate, heparin and antithrombin III injections in antithrombin III deficient patients. Thromb Res 1985; 37: 295-307.
    CrossrefPubMedGoogle Scholar